Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Friday, October 31 2014 7:54pm ET - U.S. Markets Closed.
Industry Center - Biotechnology
Industry Center > Biotechnology > Biogen Idec Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Biogen Idec Inc. Company Profile
With its pipeline full of biotech drugs, Biogen Idec aims to meet the unmet needs of patients around the world. The biotech giant is focused on developing treatments in the areas of immunology and neurology. Its product roster includes best-selling Avonex, a popular drug for the treatment of relapsing multiple sclerosis (MS); Tysabri, a drug treatment for MS and Crohn's disease; Rituxan, a monoclonal antibody developed jointly with Genentech that treats non-Hodgkin's lymphoma and rheumatoid arthritis; and Fumaderm, a psoriasis drug marketed in Germany. Biogen Idec serves customers in more than 90 countries. The company was founded in 1978.
Headlines for Biogen Idec Inc.
Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review
Thomson Reuters ONE - Fri 4:11 pm ET
4:06 pm Biogen Idec and the Swedish Orphan Biovitrum announced that the EMA has validated the Marketing Authorization Application of ELOCTA, a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A
- Fri 4:06 pm ET
Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTAâ„¢ (rFVIIIFc) Marketing Authorization Application for Review
Business Wire - Fri 4:05 pm ET
Today's Momo Momentum Stock To Watch: Biogen Idec (BIIB)
at TheStreet.com - Fri 9:50 am ET
More Headlines...
More on Biogen Idec Inc.
Quote Msgs
Chart Insider
News Financials
Profile Analyst Ratings
Research    
Contact Information
Address: 133 Boston Post Rd.
Weston, MA 02493
Phone:781-464-2000
Fax:
Financial Highlights
Fiscal Year End:December
Revenue (2013):6932.20 M
Revenue Growth (1 yr):25.70%
Employees (2013):6,850
Employee Growth (1 yr):15.10%
Key People
Chairman: Stelios Papadopoulos
CEO and Director: George A. Scangos
EVP Finance and CFO: Paul J. Clancy
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
Bayer Pharma AG
Merck Serono S.A.
Pfizer Inc. (pfe)
 


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?